Skip to content
Search

Latest Stories

PSNI launches consultation on changes to entry requirements for independent prescribing courses

The Pharmaceutical Society of Northern Ireland (PSNI) has begun a consultation on changes to requirements for training as a pharmacist independent prescriber and being annotated as an independent prescriber on the Register of Pharmaceutical Chemists.

The eight-week public consultation running was launched on Monday (April 4) and will run from until 12-noon on May 30, 2022.


The outline of the proposed consultation:

  • to decide in principle to remove the requirement set out in the Pharmaceutical Society of Northern Ireland (General) Regulations (Northern Ireland) 1994, (the Regulations), that a pharmacist must be on the Register for two years or more before they can be annotated as an IP;
  • to remove the two-year requirement for entry onto stand-alone pharmacist independent prescribing courses, contained in the Standards for the Education and Training of Independent Prescribers, replacing it with an assessment, by course providers, of competence to enter the course; and
  • to remove the requirement to have relevant experience in a specific clinical or therapeutic area and to replace it with the requirement to have relevant experience in appropriate clinical setting(s).

Dr Jim Livingstone, president of the Council of PSNI, said: “There have been significant changes in pharmacy education and training in the last 18 months. These include the introduction of new Initial Education and Training Standards for pharmacists and the introduction of a Foundation Training Year to replace pharmacist pre-registration training.

“The Governments in the United Kingdom have set a clear direction which will see pharmacist independent prescribers becoming increasingly important in the delivery of pharmacy services. This has led to one of the major changes in new standards for the initial education and training of pharmacists. Once these standards have been implemented in full, it will mean that all trainees will become independent prescribers at the point of joining our register.

“The proposed changes in this consultation arise from this development and seek to ensure that the present requirements for annotating the Register are appropriate and workable. It also makes proposals to revise the Standards for Education and Training of pharmacist independent prescribers, for stand-alone independent prescribing courses.

“The Council of the Pharmaceutical Society NI is clear that our primary objective is to protect patients and the public. We are also clear that wherever possible meeting this objective should not be an obstacle to innovation within the pharmacy profession and the development of healthcare services, which will benefit the public. We consider that the proposed changes will ensure the standards can meet the requirements of future service delivery and the development of the profession, whilst maintaining public and patient safety.

“We will continue to work closely with our colleagues in the GPhC in this important area and I would encourage pharmacists, patients and all interested groups to respond to this consultation”.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less